Thalidomide for multiple myeloma [7]

New England Journal of Medicine

Volumn 354, Issue 22, 2006, Pages 2389-2390

  Folkman, Judah ^a   Rogers, Michael S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; DRUG TOLERANCE; HUMAN; LETTER; MULTIPLE MYELOMA; PRIORITY JOURNAL; DRUG RESISTANCE; GENE EXPRESSION PROFILING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; NOTE; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MULTIPLE MYELOMA; SURVIVAL RATE; THALIDOMIDE;

EID: 33744456737     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc060958     Document Type: Letter

References (1)

1. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006;354:1021-30.